Nintedanib for non-IPF progressive pulmonary fibrosis: A systematic review and narrative synthesis of real-world effectiveness and safety
{{output}}
Background: Progressive pulmonary fibrosis (PPF) encompasses non-IPF fibrosing interstitial lung diseases that progress despite conventional management. Nintedanib is the only licensed antifibrotic for non-IPF PPF, yet real-world... ...
